Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

Study Overview
=================
Brief Summary
-----------------
This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance

Detailed Description
-----------------
This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria. Inclusion criteria: Willing to be a sample Complete medical records Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor Exclusion criteria: The patient's age is over 70 years Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others Patients with a history of brain tumor surgery or previous brain tumor treatment Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically. Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.

Official Title
-----------------
Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Diagnostic Test: Procalcitonin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to be a sample Complete medical records Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor Exclusion Criteria: The patient's age is over 70 years Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others Patients with a history of brain tumor surgery or previous brain tumor treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Meningioma Group<br>This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor. After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors. | Diagnostic Test: Procalcitonin<br>* Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically<br>* Other names: Neutrophyl to Lymphocyte Ratio (NLR);|
| Glioma Group<br>This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor. After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors. | Diagnostic Test: Procalcitonin<br>* Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically<br>* Other names: Neutrophyl to Lymphocyte Ratio (NLR);|
| Brain Metastasis Group<br>This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors. | Diagnostic Test: Procalcitonin<br>* Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically<br>* Other names: Neutrophyl to Lymphocyte Ratio (NLR);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Value of Procalcitonin | Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group) | February-April 2020 | 
| Value of C-Reactive Protein | Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group) | April- June 2020 | 
| Value of Neutrophyl to Lymphocyte Ratio (NLR) | Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group) | June- August 2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic of samples | Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score | August- October 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain Tumor, Inflammation, Procalcitonin, CRP, NLR